A major goal in AIDS research is the development of new markers to monitor HIV-1 disease progression and drug therapy, particularly during the clinically latent period. During this period, HIV-1 accumulates and actively replicates in lymphoid/organs. Development of an imaging agent for HIV-1 disease would provide a non-invasive technique to localize and quantitate HIV-1 virions and productively infected cells in the body. In the Phase I study, it was demonstrated that two radioiodinated CD4- immunoglobulin chimeric proteins, CD4-gamma2 and CD4-IgG2, bind with high affinity and specificity to the envelope glycoprotein from a laboratory- adapted strain and a primary isolate of HIV-1. In the Phase II project, the ability of these radioimmunoconjugates to bind tissue sections from HIV-1 infected individuals will be examined. The imaging agents will be tested in a novel animal model of HIV-1 envelope glycoprotein expression - - recombinant gp120/gp41 vaccina virus-infected mice. One immunoconjugate will be selected for further studies in macaques infected with simian immunodeficiency virus (SW) or simian-human immunodeficiency virus (SHIV), and chimpanzees infected with HIV-1. Finally, methods of attaching to the immunoconjugate alternative radionuclides (99MTc or 111In) will be examined. Demonstration of in vivo 'proof-of-concept' in this Phase II project would be a critical step in the preclinical development of a commercial imaging agent for use in man.

Proposed Commercial Applications

Development of an in vivo CD4-based imaging agent for HIV-1 disease to determine the distribution and burden of HIV-1 virions and infected cells in tissues for use in staging infection and disease, determining clinical prognosis and outcome, and monitoring disease progression and drug therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AI036028-03
Application #
2659087
Study Section
Special Emphasis Panel (ZRG7-SSS-4 (02))
Project Start
1994-05-01
Project End
1998-09-29
Budget Start
1997-09-30
Budget End
1998-09-29
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Progenics Pharmaceuticals, Inc.
Department
Type
DUNS #
945494490
City
Tarrytown
State
NY
Country
United States
Zip Code
10591